GPCR/G protein


All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
A9950 AnandamideSummary: An endocannabinoid -
C8444 Compound C108 -
C8446 (Rac)-VU 6008667 -
C8455 Xamoterol -
C8475 CB1R Allosteric modulator 3 -
BA7271 FriedelinSummary: Friedelin is isolated from the leaves of (Mart). -
BA4021 LaflunimusSummary: Laflunimus (HR325) is an immunosuppressant and analog of Leflunomide active metabolite A771726. -
BA4132 KR-39038Summary: KR-39038 is an orally effective (G protein-coupled receptor kinase 5) inhibitor. -
BA4280 N6,N6-DimethyladenosineSummary: N6,N6-Dimethyladenosine is a modified ribonucleoside. -
BA4296 5-Amino-5-deoxyadenosineSummary: 5'-Amino-5'-deoxyadenosine (NH2dAdo; Nsc238990) is a purine nucleoside analog.
